CANCER 2015: A Prospective, Population-based Cancer Genome Cohort (#231)

So Young Moon, John Parisot, Huiling Xu, Mark Lucas, Stephen Wong, David Choong, Chris McEvoy, Ravikiran Vedururu, Kate Crough, Kristy Barnes-Cullen, Emma Galligan, Nicole Ng, Tina Smith, Lea-Anne Harrison, Marcelle Hennig, Sandra Robinson, Jenny MacIndoe, Rachel Osborne, kConFab Investigators, The MMP InvestigatorsPaula Lorgelly, Lara Lipton, John McNeil, David Ashley, Theresa Hayes, Gary Richardson, Anthony Bell, Andrew Fellowes, David Thomas, Stephen B. Fox

Research output: Contribution to conferencePosterpeer-review


Cancer 2015 is a prospective, population-based cancer genomic cohort study. The study aims to test a new model of cancer diagnosis and treatment, with a specific focus on integrating molecular pathology into routine cancer diagnosis, treatment and research. Newly diagnosed adult patients with solid cancers are recruited into the cohort across five hospitals in Victoria, Australia, with the dataset collected including clinical, molecular pathology, health outcomes, health resource use, and health-related quality of life data. In Phase 1, we have established an upscalable cohort of 1000 patients with all mainstream solid cancer types as well as rare cancers. Molecular testing was performed using targeted exon sequencing. In Phase 2, additional 2000 patients have been recruited and protocols have been further developed to facilitate timely retrieval of specimen, molecular testing and real-time reporting. To date, over 360 real-time reports with identification of potential actionable mutations have been issued, and the utilisation of genomic data for personalised treatment and/or for enrolment into clinical trials is to be investigated when more mature data becomes available toward the end of Phase 2. In addition to its clinical utility, Cancer 2015 serves as a comprehensive cancer database providing valuable resources for cancer research. The Cancer 2015 database currently contains approximately 3000 patients and provides comprehensive demographic, epidemiological, and clinico-pathological information including previous/family cancer history, syndromes, smoking status, tumour site, stage, morphology, treatment details, and mutational data as well as health resource use and health-related quality of life data which are collected at diagnosis, 6 months after diagnosis, and yearly thereafter. The Cancer 2015 bio-specimen and data are available to the cancer research community through a formal application. More details of Cancer 2015 mutational profiles are outlined in the abstract entitled “Cancer genetic mutation profiling in Cancer 2015 cohort” (abstract #42378). Information about the available resources and the access process is available at
Original languageEnglish
Number of pages1
Publication statusPublished - 2017
EventLorne Cancer Conference 2017 - Mantra Lorne Hotel, Lorne, Australia
Duration: 9 Feb 201711 Feb 2017
Conference number: 29th


ConferenceLorne Cancer Conference 2017

Cite this